Retrain the Brain.
Restore Swallowing Control.

Phagenyx® improves swallowing safety and efficiency to accelerate recovery from post-stroke dysphagia.

friendly female pediatrician touches shoulder teenage
friendly female pediatrician touches shoulder teenage

Dysphagia is Common, Costly and Harmful

Dysphagia is a significant and costly barrier to stroke recovery and is linked to prolonged hospitalization, increased healthcare costs and aspiration-related complications.

10

day longer hospital stay¹

day longer hospital stay¹

day longer hospital stay¹

$36

k

additional cost per patient²

additional cost per patient²

8

higher mortality at 3 months³

higher mortality at 3 months³

How It Works

How It Works

1

Stimulation of sensory nerves

2

Signals excite motor cortex

3

Excitation drives neuroplasticity

4

Swallowing control is restored

A New Approach to Improving Swallow Safety and Efficiency

Pharyngeal electrical stimulation (PES) is a targeted therapy that delivers low-level electrical impulses to the swallowing nerves in the throat, helping re-establish communication with the brain and promote neuroplasticity to restore swallowing control.⁴

What Phagenyx does

The Phagenyx System improves swallowing safety and efficiency by restoring the brain’s ability to initiate and coordinate safe swallowing, accelerating recovery from post-stroke dysphagia.

Promotes Neurologic Recovery

Phagenyx applies pharyngeal electrical stimulation (PES) to the sensory nerves and restores the brain’s control of swallowing function.

Improves Swallowing Safety & Efficiency

Clinical studies show Phagenyx enables faster return to oral nutrition and reduces aspiration risk, supporting shorter hospital stays.

Designed for Real-World Care

Phagenyx enables early intervention without disrupting clinical workflow – even for critically ill patients.

2

Improved Swallowing Safety⁶

Improved Swallowing Safety⁶

6 days

Faster Return to Oral Nutrition⁵

Faster Return to Oral Nutrition⁵

8 days

Shorter length of hospital stay⁷

Fewer in the Hospital9

Fewer in the Hospital9

5 days

Shorter length of ICU Stay⁸

Fewer in the ICU9

Fewer in the ICU9

smiling happily caregiver hugging her old

Who it's for

Phagenyx may be appropriate for patients with reduced or absent spontaneous swallowing, impaired swallowing safety and efficiency, or abnormal sensation in the pharynx or larynx.

Ready to transform your approach to post-stroke dysphagia recovery? Bring Phagenyx to your hospital.

Testimonials

Get in Touch

Are you a healthcare provider interested in bringing Phagenyx® to your facility? Or are you a professional ready to join us on our mission to change the future of dysphagia care? We’re ready to connect with you.

The content on this website is intended for healthcare providers and may not be approved for use in your specific region or country. Phagenesis is not responsible for any interactions or dealings you have via this website that do not comply with applicable laws and regulations in your jurisdiction. By continuing to use this website, you acknowledge and agree to the terms of this notice.

Manufacturer; Phagenesis Ltd, Enterprise House, Manchester Science Park, Manchester, M15 6SE, UK

1. Centers for Medicare & Medicaid Services (CMS). Medicare Provider Analysis and Review (MedPAR) File. Fiscal Year 2023. 2. Vasan V, et al. J Stroke Cerebrovasc Dis. 2023;32(9):107295. 3. Arnold M, et al. PLoS One. 2016;11(2):e0148424. 4. Fraser C, et al. Neuron. 2002;34(5):831–840. 5. Suntrup-Krueger S, et al. Crit Care. 2023;27(1):383. 6. Youssef G, et al. Al-Azhar Assiut Med J. 2015;13(1):68–72. 7. Suntrup-Krueger S, et al. Crit Care. 2025;May 17:e00613. 8. Suntrup-Krueger et al. Crit Care. 2023;27(1):383.

Indications for Use (Europe/UK/Switzerland): The Phagenyx System (EPSB3 Base Station and PNX-1000 catheter) is to be used for the treatment of neurogenic dysphagia in adult patients.

For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product.

Indications for Use (US): Phagenyx is a neurostimulation device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke.

Federal law in the US restricts this device to sale by or on the order of a physician. For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product. The content on this website is intended for healthcare providers and may not be approved for use in your specific region or country. Phagenesis is not responsible for any interactions or dealings you have via this website that do not comply with applicable laws and regulations in your jurisdiction. By continuing to use this website, you acknowledge and agree to the terms of this notice.

© Phagenesis Inc. 2026. All rights reserved.

FDA has provided de novo classification for the Phagenyx® System and it is available for sale in the United States.



© Phagenesis Limited 2026. All rights reserved.

The Phagenyx® system is CE marked and is available for sale only in the European Economic Area, UK and Switzerland.

Manufacturer; Phagenesis Ltd, Enterprise House, Manchester Science Park, Manchester, M15 6SE, UK

1. Centers for Medicare & Medicaid Services (CMS). Medicare Provider Analysis and Review (MedPAR) File. Fiscal Year 2023. 2. Vasan V, et al. J Stroke Cerebrovasc Dis. 2023;32(9):107295. 3. Arnold M, et al. PLoS One. 2016;11(2):e0148424. 4. Fraser C, et al. Neuron. 2002;34(5):831–840. 5. Suntrup-Krueger S, et al. Crit Care. 2023;27(1):383. 6. Youssef G, et al. Al-Azhar Assiut Med J. 2015;13(1):68–72. 7. Suntrup-Krueger S, et al. Crit Care. 2025;May 17:e00613. 8. Suntrup-Krueger et al. Crit Care. 2023;27(1):383.

Indications for Use (Europe/UK/Switzerland): The Phagenyx System (EPSB3 Base Station and PNX-1000 catheter) is to be used for the treatment of neurogenic dysphagia in adult patients.

For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product.

Indications for Use (US): Phagenyx is a neurostimulation device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke.

Federal law in the US restricts this device to sale by or on the order of a physician. For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product. The content on this website is intended for healthcare providers and may not be approved for use in your specific region or country. Phagenesis is not responsible for any interactions or dealings you have via this website that do not comply with applicable laws and regulations in your jurisdiction. By continuing to use this website, you acknowledge and agree to the terms of this notice.

© Phagenesis Inc. 2026. All rights reserved.

FDA has provided de novo classification for the Phagenyx® System and it is available for sale in the United States.



© Phagenesis Limited 2026. All rights reserved.

The Phagenyx® system is CE marked and is available for sale only in the European Economic Area, UK and Switzerland.

Manufacturer; Phagenesis Ltd, Enterprise House, Manchester Science Park, Manchester, M15 6SE, UK

1. Centers for Medicare & Medicaid Services (CMS). Medicare Provider Analysis and Review (MedPAR) File. Fiscal Year 2023. 2. Vasan V, et al. J Stroke Cerebrovasc Dis. 2023;32(9):107295. 3. Arnold M, et al. PLoS One. 2016;11(2):e0148424. 4. Fraser C, et al. Neuron. 2002;34(5):831–840. 5. Suntrup-Krueger S, et al. Crit Care. 2023;27(1):383. 6. Youssef G, et al. Al-Azhar Assiut Med J. 2015;13(1):68–72. 7. Suntrup-Krueger S, et al. Crit Care. 2025;May 17:e00613. 8. Suntrup-Krueger et al. Crit Care. 2023;27(1):383.

Indications for Use (Europe/UK/Switzerland): The Phagenyx System (EPSB3 Base Station and PNX-1000 catheter) is to be used for the treatment of neurogenic dysphagia in adult patients.

For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product.

Indications for Use (US): Phagenyx is a neurostimulation device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke.

Federal law in the US restricts this device to sale by or on the order of a physician. For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product. The content on this website is intended for healthcare providers and may not be approved for use in your specific region or country. Phagenesis is not responsible for any interactions or dealings you have via this website that do not comply with applicable laws and regulations in your jurisdiction. By continuing to use this website, you acknowledge and agree to the terms of this notice.

© Phagenesis Inc. 2026. All rights reserved.

FDA has provided de novo classification for the Phagenyx® System and it is available for sale in the United States.



© Phagenesis Limited 2026. All rights reserved.

The Phagenyx® system is CE marked and is available for sale only in the European Economic Area, UK and Switzerland.